The patient presented here initially developed dyspnea and malaise but no fever. These nonspecific symptoms in the early clinical course of are difficult to distinguish from other common respiratory viral infections. In addition, our patient's progression to severe pneumonia was on day 8 of illness. Such an evolution at a median 8 days from onset was reported in a recent publication 8 .
The inflammatory response in CoVID-19 is characterized by deep airway and alveolar injury, the chest imaging showing ground glass opacities, especially in the lung periphery. By February 24 th , 2020, the national lethality of Covid-19 was 3.17% 9 .
Although a decision was made to use acyclovir, interferon-α and a traditional Chinese medicine, randomized controlled trials are needed to prove the safety and efficacy of these therapies. Our experts are researching other agents for treatment of patients with COVID-19. Finally, our patient developed unusual symptoms including reduced muscle strength and elevated myoglobin level. Whether these symptoms are caused by SARS-CoV-2 is yet uncertain. Consent for publication ： All authors have read and approved the manuscript version, and agree to submit for consideration for publication in the journal. We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.
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